Clinical trial
Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis
NCT00432861 · Digestive Care, Inc., Industry · Completed
Key facts
| NCT number | NCT00432861 |
|---|---|
| Title | Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Crossover Study to Evaluate the Effectiveness and Safety of PANCRECARB® MS-16 (Pancrelipase) in Reducing Steatorrhea in Children and Adults With Cystic Fibrosis |
| Lead sponsor | Digestive Care, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis, Pancreatic Insufficiency |
| Intervention type | Drug |
| Interventions | PANCRECARB® (pancrelipase), Placebo |
| Enrollment | 29 |
| Start date | Jan 1, 2007 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Feb 8, 2007 |
| Last update posted | Feb 22, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: